Cargando…
Statin Effects to Reduce Hepatosteatosis as Measured by Computed Tomography in Patients With Human Immunodeficiency Virus
Hepatosteatosis is highly prevalent among patients living with human immunodeficiency virus. In a 1-year, randomized, double-blind trial of atorvastatin or placebo, atorvastatin increased liver/spleen ratio among patients with nonalcoholic fatty liver disease, indicating a reduction in hepatosteatos...
Autores principales: | Lo, Janet, Lu, Michael T., Kim, Elli A., Nou, Eric, Hallett, Travis R., Park, Jakob, Hoffmann, Udo, Grinspoon, Steven K. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4943550/ https://www.ncbi.nlm.nih.gov/pubmed/27419149 http://dx.doi.org/10.1093/ofid/ofw062 |
Ejemplares similares
-
Pathophysiology and Management of Cardiovascular Disease in HIV-Infected Patients
por: Nou, Eric, et al.
Publicado: (2016) -
Early induction of hepatic deiodinase type 1 inhibits hepatosteatosis during NAFLD progression
por: Bruinstroop, Eveline, et al.
Publicado: (2021) -
Monomeric GLP-1/GIP/glucagon triagonism corrects obesity, hepatosteatosis, and dyslipidemia in female mice
por: Jall, Sigrid, et al.
Publicado: (2017) -
Ceramides: Nutrient Signals that Drive Hepatosteatosis
por: Summers, Scott A.
Publicado: (2020) -
Impact of the American College of Cardiology/American Heart Association Cholesterol Guidelines on Statin Eligibility Among Human Immunodeficiency Virus-Infected Individuals
por: Mosepele, Mosepele, et al.
Publicado: (2018)